GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » TearLab Corp (OTCPK:TEAR) » Definitions » ROC (Joel Greenblatt) %

TearLab (TearLab) ROC (Joel Greenblatt) % : -14.23% (As of Mar. 2020)


View and export this data going back to 2004. Start your Free Trial

What is TearLab ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. TearLab's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2020 was -14.23%.

The historical rank and industry rank for TearLab's ROC (Joel Greenblatt) % or its related term are showing as below:

TEAR's ROC (Joel Greenblatt) % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -15.21
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

TearLab's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


TearLab ROC (Joel Greenblatt) % Historical Data

The historical data trend for TearLab's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TearLab ROC (Joel Greenblatt) % Chart

TearLab Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -614.47 -300.58 -306.69 88.27 8.25

TearLab Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.05 33.06 -40.82 40.08 -14.23

Competitive Comparison of TearLab's ROC (Joel Greenblatt) %

For the Diagnostics & Research subindustry, TearLab's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TearLab's ROC (Joel Greenblatt) % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, TearLab's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where TearLab's ROC (Joel Greenblatt) % falls into.



TearLab ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.917 + 2.269 + 1.562) - (1.521 + 0.002 + 1.414)
=1.811

Working Capital(Q: Mar. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.936 + 1.948 + 1.449) - (2.207 + 0.001 + 0.691)
=1.434

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of TearLab for the quarter that ended in Mar. 2020 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2020 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2019  Q: Mar. 2020
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.56/( ( (2.315 + max(1.811, 0)) + (2.31 + max(1.434, 0)) )/ 2 )
=-0.56/( ( 4.126 + 3.744 )/ 2 )
=-0.56/3.935
=-14.23 %

Note: The EBIT data used here is four times the quarterly (Mar. 2020) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TearLab  (OTCPK:TEAR) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


TearLab ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of TearLab's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


TearLab (TearLab) Business Description

Traded in Other Exchanges
N/A
Address
150 LaTerraza Boulevard, Suite 101, Escondido, CA, USA, 92025
TearLab Corp is a part of the diagnostic industry. It is an in-vitro diagnostic company based in the United States. TearLab has commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The company operates through its wholly-owned subsidiary, TearLab Research Inc. Most of the company's revenue is derived from the United States region.
Executives
Anthony E Altig director C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, JERSEY CITY NJ 07302
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
John Y Caloz officer: Chief Financial Officer ETON AVE, C/O INTERNATIONAL REMOTE IMAGING SYS, CHATSWORTH CA 91311